FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239867012> ?p ?o ?g. }

• W4239867012 abstract "Background Pseudomonas aeruginosa is the most common bacterial pathogen causing lung infections in people with CF and appropriate antibiotic therapy is vital. Antibiotics for pulmonary exacerbations are usually given intravenously, and for long‐term treatment, via a nebuliser. Oral anti‐pseudomonal antibiotics with the same efficacy and safety as intravenous or nebulised antibiotics would benefit people with CF due to ease of treatment and avoidance of hospitalisation. Objectives To determine the benefit or harm of oral anti‐pseudomonal antibiotic therapy for people with CF, colonised with Pseudomonas aeruginosa, in the: 1. treatment of a pulmonary exacerbation; and 2. long‐term treatment of chronic infection. Search methods We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We contacted pharmaceutical companies and checked reference lists of identified trials. Last search: 22 April 2010. Selection criteria Randomised or quasi‐randomised controlled trials comparing any dose of oral anti‐pseudomonal antibiotics, to other combinations of inhaled, oral or intravenous antibiotics, or to placebo or usual treatment for pulmonary exacerbations and long‐term treatment. Data collection and analysis Two authors independently selected the trials, extracted data and assessed quality. We contacted trialists to obtain missing information. Main results We included three trials examining pulmonary exacerbations (171 participants) and two trials examining long‐term therapy (85 participants). We regarded the most important outcomes as quality of life and lung function. The analysis did not identify any statistically significant difference between oral anti‐pseudomonal antibiotics and other treatments for these outcome measures for either pulmonary exacerbations or long‐term treatment. One of the included trials reported significantly better lung function when treating a pulmonary exacerbation with ciprofloxacin when compared with intravenous treatment; however, our analysis did not confirm this finding. We found no evidence of difference between oral anti‐pseudomonal antibiotics and other treatments regarding adverse events or development of antibiotic resistance, but trials were not adequately powered to detect this. Authors' conclusions We found no conclusive evidence that an oral anti‐pseudomonal antibiotic regimen is more or less effective than an alternative treatment for either pulmonary exacerbations or long‐term treatment of chronic infection with P. aeruginosa. Until results of adequately‐powered future trials are available, treatment needs to be selected on a pragmatic basis, based upon any available non‐RCT evidence, the clinical circumstances of the individual, the known effectiveness of drugs against local strains and upon individual preference." @default.
• W4239867012 created "2022-05-12" @default.
• W4239867012 creator A5018177147 @default.
• W4239867012 creator A5036199016 @default.
• W4239867012 creator A5044947060 @default.
• W4239867012 date "2007-07-18" @default.
• W4239867012 modified "2023-09-23" @default.
• W4239867012 title "Oral anti-pseudomonal antibiotics for cystic fibrosis" @default.
• W4239867012 cites W1551716756 @default.
• W4239867012 cites W1966248805 @default.
• W4239867012 cites W1970511260 @default.
• W4239867012 cites W1981885570 @default.
• W4239867012 cites W1982420680 @default.
• W4239867012 cites W1983220809 @default.
• W4239867012 cites W1986937077 @default.
• W4239867012 cites W2003916900 @default.
• W4239867012 cites W2004068262 @default.
• W4239867012 cites W2008586082 @default.
• W4239867012 cites W2008726834 @default.
• W4239867012 cites W2020679896 @default.
• W4239867012 cites W2022942176 @default.
• W4239867012 cites W2024387454 @default.
• W4239867012 cites W2039971924 @default.
• W4239867012 cites W2043306398 @default.
• W4239867012 cites W2045336828 @default.
• W4239867012 cites W204803990 @default.
• W4239867012 cites W2050577849 @default.
• W4239867012 cites W2051263691 @default.
• W4239867012 cites W2055857822 @default.
• W4239867012 cites W2057046567 @default.
• W4239867012 cites W2057496127 @default.
• W4239867012 cites W2057655335 @default.
• W4239867012 cites W2059953204 @default.
• W4239867012 cites W2061909665 @default.
• W4239867012 cites W2062510102 @default.
• W4239867012 cites W2063154763 @default.
• W4239867012 cites W2066118039 @default.
• W4239867012 cites W2075106983 @default.
• W4239867012 cites W2078851114 @default.
• W4239867012 cites W2088190606 @default.
• W4239867012 cites W2088411382 @default.
• W4239867012 cites W2088849723 @default.
• W4239867012 cites W2090000999 @default.
• W4239867012 cites W2090648579 @default.
• W4239867012 cites W2096869709 @default.
• W4239867012 cites W2109710305 @default.
• W4239867012 cites W2111598008 @default.
• W4239867012 cites W2121124570 @default.
• W4239867012 cites W2123178771 @default.
• W4239867012 cites W2123796047 @default.
• W4239867012 cites W2125435699 @default.
• W4239867012 cites W2129259127 @default.
• W4239867012 cites W2130235475 @default.
• W4239867012 cites W2138927620 @default.
• W4239867012 cites W2142930532 @default.
• W4239867012 cites W2151174404 @default.
• W4239867012 cites W2155069031 @default.
• W4239867012 cites W2166779461 @default.
• W4239867012 cites W2168849280 @default.
• W4239867012 cites W2171230591 @default.
• W4239867012 cites W4235038734 @default.
• W4239867012 doi "https://doi.org/10.1002/14651858.cd005405.pub2" @default.
• W4239867012 hasPublicationYear "2007" @default.
• W4239867012 type Work @default.
• W4239867012 citedByCount "7" @default.
• W4239867012 countsByYear W42398670122013 @default.
• W4239867012 countsByYear W42398670122016 @default.
• W4239867012 crossrefType "reference-entry" @default.
• W4239867012 hasAuthorship W4239867012A5018177147 @default.
• W4239867012 hasAuthorship W4239867012A5036199016 @default.
• W4239867012 hasAuthorship W4239867012A5044947060 @default.
• W4239867012 hasConcept C126322002 @default.
• W4239867012 hasConcept C142724271 @default.
• W4239867012 hasConcept C177713679 @default.
• W4239867012 hasConcept C204787440 @default.
• W4239867012 hasConcept C27081682 @default.
• W4239867012 hasConcept C2776938444 @default.
• W4239867012 hasConcept C2777014857 @default.
• W4239867012 hasConcept C2777637488 @default.
• W4239867012 hasConcept C501593827 @default.
• W4239867012 hasConcept C523546767 @default.
• W4239867012 hasConcept C535046627 @default.
• W4239867012 hasConcept C54355233 @default.
• W4239867012 hasConcept C71924100 @default.
• W4239867012 hasConcept C86803240 @default.
• W4239867012 hasConcept C89423630 @default.
• W4239867012 hasConceptScore W4239867012C126322002 @default.
• W4239867012 hasConceptScore W4239867012C142724271 @default.
• W4239867012 hasConceptScore W4239867012C177713679 @default.
• W4239867012 hasConceptScore W4239867012C204787440 @default.
• W4239867012 hasConceptScore W4239867012C27081682 @default.
• W4239867012 hasConceptScore W4239867012C2776938444 @default.
• W4239867012 hasConceptScore W4239867012C2777014857 @default.
• W4239867012 hasConceptScore W4239867012C2777637488 @default.
• W4239867012 hasConceptScore W4239867012C501593827 @default.
• W4239867012 hasConceptScore W4239867012C523546767 @default.
• W4239867012 hasConceptScore W4239867012C535046627 @default.
• W4239867012 hasConceptScore W4239867012C54355233 @default.
• W4239867012 hasConceptScore W4239867012C71924100 @default.
• W4239867012 hasConceptScore W4239867012C86803240 @default.

• next